← All trials
NCT05696548
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 2, 2019
- Primary completion
- Jul 31, 2025
- Completion date
- Jul 31, 2025
- First posted
- Jan 25, 2023
- Last posted
- Jan 25, 2023
- Enrollment
- 51
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- National Cancer Center, JapanLead sponsor
- Kobe UniversityStudy chair
- National Cancer Center, JapanReponsible party - principal investigator
- National Cancer Center, JapanStudy director
- Ono PharmaceuticalsCollaborator
- National Cancer Center, JapanSponsor investigator
- Kobe UniversityOfficial
- National Cancer Center, JapanOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.